首页 > 最新文献

Rare Tumors最新文献

英文 中文
A rare case of synchronous follicular thyroid carcinoma arising within a mature cystic ovarian teratoma and stage IV differentiated thyroid cancer in iodine-deficient area in Viet Nam. 越南缺碘地区发生于成熟囊性卵巢畸胎瘤及分化期甲状腺癌的同步滤泡性甲状腺癌1例。
IF 0.9 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.1177/20363613231161940
Phong Hong Nguyen, Thang Nguyen, Chien Minh Pham

Well-differentiated thyroid carcinoma rarely spreads to soft tissues. Thyroid carcinoma arising within a mature cystic teratoma is even rarer. We report an extremely rare case of synchronous follicular thyroid carcinoma arising within a mature cystic ovarian teratoma and stage IV differentiated thyroid carcinoma. A 62-year-old woman who lived in an iodine-deficient area was accidentally diagnosed with an ovarian cyst during a radiological metastatic work-up for thyroid cancer. Following laparoscopic left salpingo-oophorectomy, histopathological examination revealed a follicular thyroid carcinoma arising within a mature cystic teratoma. After that, total thyroidectomy and surgical resection of the soft tissue lesion in the supraclavicular fossa were performed, and the patient received subsequent 131I ablation therapy, but the disease progression was recorded 3 months later. We believe that iodine deficiency plays a role in the malignant transformation of thyroid tissues within a mature cystic teratoma. In elderly individuals with significant metastases, radioactive iodine therapy is ineffective.

高分化甲状腺癌很少扩散到软组织。甲状腺癌发生在成熟的囊性畸胎瘤是更罕见的。我们报告一例极为罕见的同步滤泡性甲状腺癌发生在成熟的卵巢畸胎瘤和IV期分化甲状腺癌。一位居住在缺碘地区的62岁妇女在甲状腺癌的放射转移检查中被意外诊断为卵巢囊肿。腹腔镜左输卵管卵巢切除术后,组织病理学检查显示成熟囊性畸胎瘤内出现滤泡性甲状腺癌。术后行甲状腺全切除术及锁骨上窝软组织病变手术切除,患者后续接受131I消融治疗,3个月后记录病情进展。我们认为碘缺乏在成熟囊性畸胎瘤中甲状腺组织的恶性转化中起作用。对于有明显转移的老年人,放射性碘治疗无效。
{"title":"A rare case of synchronous follicular thyroid carcinoma arising within a mature cystic ovarian teratoma and stage IV differentiated thyroid cancer in iodine-deficient area in Viet Nam.","authors":"Phong Hong Nguyen,&nbsp;Thang Nguyen,&nbsp;Chien Minh Pham","doi":"10.1177/20363613231161940","DOIUrl":"https://doi.org/10.1177/20363613231161940","url":null,"abstract":"<p><p>Well-differentiated thyroid carcinoma rarely spreads to soft tissues. Thyroid carcinoma arising within a mature cystic teratoma is even rarer. We report an extremely rare case of synchronous follicular thyroid carcinoma arising within a mature cystic ovarian teratoma and stage IV differentiated thyroid carcinoma. A 62-year-old woman who lived in an iodine-deficient area was accidentally diagnosed with an ovarian cyst during a radiological metastatic work-up for thyroid cancer. Following laparoscopic left salpingo-oophorectomy, histopathological examination revealed a follicular thyroid carcinoma arising within a mature cystic teratoma. After that, total thyroidectomy and surgical resection of the soft tissue lesion in the supraclavicular fossa were performed, and the patient received subsequent <sup>131</sup>I ablation therapy, but the disease progression was recorded 3 months later. We believe that iodine deficiency plays a role in the malignant transformation of thyroid tissues within a mature cystic teratoma. In elderly individuals with significant metastases, radioactive iodine therapy is ineffective.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"15 ","pages":"20363613231161940"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/28/10.1177_20363613231161940.PMC9989423.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9085852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lymphangitic carcinomatosis as the initial manifestation of primary signet-ring cell adenocarcinoma of the lung: A case report. 以原发性肺印戒细胞腺癌为首发表现的淋巴管癌1例。
IF 0.9 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.1177/20363613231164017
David Corredor-Orlandelli, Lina Vargas

Signet-ring cell carcinomas are an aggressive, poorly differentiated, and highly invasive adenocarcinoma carrying a poor prognosis. Most of these tumors originate in gastrointestinal organs; however, primary lung signet-ring cell adenocarcinomas can rarely occur. Tumoral lymphatic infiltration is a complication of these tumors and can cause phenomena such as lymphangitic carcinomatosis, characterized by a nodular thickening of the pleura, pleural effusions, and mediastinal lymphadenopathies. We report a case of a 63-year-old ex-smoker with a 2-week clinical course of dyspnea and pleuritic chest pain in which a nodular thickening of the pleura and pleural effusion were documented and led to the diagnosis of a primary signet-ring cell adenocarcinoma of the lung with lymphangitic carcinomatosis. This complication has never been described in the context of a primary lung tumor of this subtype. Both entities carry a high mortality and have no therapeutical options. This report adds to the information available about them.

印戒细胞癌是一种侵袭性、低分化、高侵袭性的腺癌,预后差。这些肿瘤大多起源于胃肠道器官;然而,原发性肺印戒细胞腺癌很少发生。肿瘤淋巴浸润是这些肿瘤的并发症,可引起淋巴管癌病等现象,其特征是胸膜结节性增厚、胸膜积液和纵隔淋巴结病。我们报告一例63岁的前吸烟者,有2周的临床病程,呼吸困难和胸膜炎性胸痛,胸膜结节增厚和胸膜积液,并导致原发性肺印戒细胞腺癌合并淋巴管癌病的诊断。这种并发症从未在这种亚型的原发性肺肿瘤中被描述过。这两种疾病的死亡率都很高,而且没有治疗选择。这份报告增加了关于他们的可用信息。
{"title":"Lymphangitic carcinomatosis as the initial manifestation of primary signet-ring cell adenocarcinoma of the lung: A case report.","authors":"David Corredor-Orlandelli,&nbsp;Lina Vargas","doi":"10.1177/20363613231164017","DOIUrl":"https://doi.org/10.1177/20363613231164017","url":null,"abstract":"<p><p>Signet-ring cell carcinomas are an aggressive, poorly differentiated, and highly invasive adenocarcinoma carrying a poor prognosis. Most of these tumors originate in gastrointestinal organs; however, primary lung signet-ring cell adenocarcinomas can rarely occur. Tumoral lymphatic infiltration is a complication of these tumors and can cause phenomena such as lymphangitic carcinomatosis, characterized by a nodular thickening of the pleura, pleural effusions, and mediastinal lymphadenopathies. We report a case of a 63-year-old ex-smoker with a 2-week clinical course of dyspnea and pleuritic chest pain in which a nodular thickening of the pleura and pleural effusion were documented and led to the diagnosis of a primary signet-ring cell adenocarcinoma of the lung with lymphangitic carcinomatosis. This complication has never been described in the context of a primary lung tumor of this subtype. Both entities carry a high mortality and have no therapeutical options. This report adds to the information available about them.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"15 ","pages":"20363613231164017"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/08/10.1177_20363613231164017.PMC10014970.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9152994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conference Report: European Society for Medical Oncology Congress 2022. 会议报告:2022年欧洲肿瘤医学学会大会。
IF 0.9 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.1177/20363613231162474
Sevda Dogan

The European Society of Medical Oncology took place in Paris Convention Centre, Paris, France on 9th -13th September 2022 and was attended by more than 28,000 delegates, 23,000 of which were in person and 5000 online. This was the first on-site ESMO congress after the COVID-19 pandemic. This report focuses on a selection of talks delivered at the conference. There was a vast collection of interesting talks, nevertheless, I attended talks that focused on rare cancers.

欧洲肿瘤医学学会会议于2022年9月9日至13日在法国巴黎巴黎会议中心举行,有28,000多名代表参加,其中23,000名代表亲自出席,5000名代表在线出席。这是2019冠状病毒病大流行后首次在ESMO现场召开大会。本报告集中报道了在会议上发表的一些谈话。有很多有趣的演讲,然而,我参加的是关于罕见癌症的演讲。
{"title":"Conference Report: European Society for Medical Oncology Congress 2022.","authors":"Sevda Dogan","doi":"10.1177/20363613231162474","DOIUrl":"https://doi.org/10.1177/20363613231162474","url":null,"abstract":"<p><p>The European Society of Medical Oncology took place in Paris Convention Centre, Paris, France on 9th -13th September 2022 and was attended by more than 28,000 delegates, 23,000 of which were in person and 5000 online. This was the first on-site ESMO congress after the COVID-19 pandemic. This report focuses on a selection of talks delivered at the conference. There was a vast collection of interesting talks, nevertheless, I attended talks that focused on rare cancers.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"15 ","pages":"20363613231162474"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/ce/10.1177_20363613231162474.PMC9989427.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9093093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An incidental discovery of a gastric follicular dendritic cell sarcoma: A rare case report and a literature review. 偶然发现的胃滤泡树突状细胞肉瘤:罕见病例报告及文献复习。
IF 0.9 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.1177/20363613231172077
Farah Sassi, Ghada Sahraoui, Lamia Charfi, Leila Achouri, Raoudha Doghri, Karima Mrad

Introduction: Follicular dendritic cell sarcomas (FDCS) are rare tumours, typically seen in lymph nodes. However, in about one third of the reported cases, a FDCS presents as an extranodal mass. Involvement of the gastrointestinal tract is rare, and the stomach is even rarer with only four cases described to date. The aim of this study was to review clinical characteristics, pathologic features, emphasize on differential diagnosis and discuss therapeutic modalities and prognosis of this rare entity.Case presentation: We report on a 36-year-old female patient with no past medical history, an incidentally discovered FDCS located in the stomach with the presence of lymph node metastasis at the time of diagnosis. The diagnosis of a FDCS was made on morphological and immunohistochemical findings where tumor cells expressed CD21 and CD23. The tumor was resected by gastrectomy with extended para-aortic lymphadenectomy, with uneventful postoperative course.Conclusions: Due to its rarity, FDCS is rarely included in the differential diagnosis of gastrointestinal spindle cell tumors. Complete surgical resection is the current gold standard of treatment.

简介:滤泡树突状细胞肉瘤(FDCS)是一种罕见的肿瘤,多见于淋巴结。然而,在大约三分之一的报告病例中,FDCS表现为结外肿块。累及胃肠道的病例很少见,而累及胃的病例则更为罕见,迄今为止仅有4例。本研究的目的是回顾临床特点,病理特征,强调鉴别诊断,并讨论治疗方式和预后这种罕见的实体。病例介绍:我们报告一位36岁女性患者,无既往病史,在诊断时偶然发现位于胃的FDCS并伴有淋巴结转移。FDCS的诊断是通过肿瘤细胞表达CD21和CD23的形态学和免疫组织化学结果进行的。经胃切除术合并腹主动脉旁淋巴结切除术,手术过程顺利。结论:由于FDCS的罕见性,它很少被纳入胃肠道梭形细胞瘤的鉴别诊断。完全手术切除是目前治疗的金标准。
{"title":"An incidental discovery of a gastric follicular dendritic cell sarcoma: A rare case report and a literature review.","authors":"Farah Sassi,&nbsp;Ghada Sahraoui,&nbsp;Lamia Charfi,&nbsp;Leila Achouri,&nbsp;Raoudha Doghri,&nbsp;Karima Mrad","doi":"10.1177/20363613231172077","DOIUrl":"https://doi.org/10.1177/20363613231172077","url":null,"abstract":"<p><p><b>Introduction:</b> Follicular dendritic cell sarcomas (FDCS) are rare tumours, typically seen in lymph nodes. However, in about one third of the reported cases, a FDCS presents as an extranodal mass. Involvement of the gastrointestinal tract is rare, and the stomach is even rarer with only four cases described to date. The aim of this study was to review clinical characteristics, pathologic features, emphasize on differential diagnosis and discuss therapeutic modalities and prognosis of this rare entity.<b>Case presentation:</b> We report on a 36-year-old female patient with no past medical history, an incidentally discovered FDCS located in the stomach with the presence of lymph node metastasis at the time of diagnosis. The diagnosis of a FDCS was made on morphological and immunohistochemical findings where tumor cells expressed CD21 and CD23. The tumor was resected by gastrectomy with extended para-aortic lymphadenectomy, with uneventful postoperative course.<b>Conclusions:</b> Due to its rarity, FDCS is rarely included in the differential diagnosis of gastrointestinal spindle cell tumors. Complete surgical resection is the current gold standard of treatment.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"15 ","pages":"20363613231172077"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bf/d0/10.1177_20363613231172077.PMC10134144.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9450501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment approaches for urachal cancer: Use of immunotherapy and targeted therapies. 尿管癌的治疗方法:使用免疫治疗和靶向治疗。
IF 0.9 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.1177/20363613231189984
David J Benjamin, Arash Rezazadeh Kalebasty

Urachal cancer is a rare genitourinary malignancy that arises from the embryologic remnant of the urachus. The malignancy is considered to be aggressive, with no clear consensus on appropriate management for advanced disease. Although traditionally considered to be related to bladder cancer given its embryologic origin, several next generation sequencing studies have revealed the genomic profile of this genitourinary malignancy most closely resembles colorectal cancer. Moreover, these studies have identified potentially actionable mutations including EGFR, KRAS and MET. In addition, recent data suggests that immunotherapy may benefit some patients with advanced urachal cancer. Nonetheless, continued research is warranted to better understand how to treat this rare genitourinary cancer.

尿管癌是一种罕见的泌尿生殖系统恶性肿瘤,起源于胚胎残余的尿管。恶性肿瘤被认为是侵袭性的,对于晚期疾病的适当治疗没有明确的共识。虽然传统上认为由于其胚胎起源与膀胱癌有关,但几项下一代测序研究揭示了这种泌尿生殖系统恶性肿瘤的基因组图谱与结直肠癌最相似。此外,这些研究已经确定了潜在的可操作突变,包括EGFR, KRAS和MET。此外,最近的数据表明免疫疗法可能使一些晚期尿管癌患者受益。尽管如此,为了更好地了解如何治疗这种罕见的泌尿生殖系统癌,需要继续进行研究。
{"title":"Treatment approaches for urachal cancer: Use of immunotherapy and targeted therapies.","authors":"David J Benjamin,&nbsp;Arash Rezazadeh Kalebasty","doi":"10.1177/20363613231189984","DOIUrl":"https://doi.org/10.1177/20363613231189984","url":null,"abstract":"<p><p>Urachal cancer is a rare genitourinary malignancy that arises from the embryologic remnant of the urachus. The malignancy is considered to be aggressive, with no clear consensus on appropriate management for advanced disease. Although traditionally considered to be related to bladder cancer given its embryologic origin, several next generation sequencing studies have revealed the genomic profile of this genitourinary malignancy most closely resembles colorectal cancer. Moreover, these studies have identified potentially actionable mutations including EGFR, KRAS and MET. In addition, recent data suggests that immunotherapy may benefit some patients with advanced urachal cancer. Nonetheless, continued research is warranted to better understand how to treat this rare genitourinary cancer.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"15 ","pages":"20363613231189984"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/c0/10.1177_20363613231189984.PMC10350764.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10353625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
KEYNOTE-522 and male spindle cell carcinoma of the breast: A case report. KEYNOTE-522与男性乳腺梭形细胞癌:1例报告。
IF 0.9 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.1177/20363613231163730
Harper E Niver, Edward Foxhall, Anup Lahiry

Metaplastic Breast Cancer (MBC) is a rare group of tumors often presenting as triple-negative. MBC accounts for less than 1% of all breast cancers with the spindle cell variant comprising less than 0.5%. While rare, spindle cell carcinoma is the commonest subtype in the western world. It has a more aggressive biological behavior with increased risk of recurrence and death due to disease compared to triple negative breast cancers. There is no treatment guideline for management of MBC due to the rarity of the disease. Instead, treatment is theorized based off success with other types of aggressive breast and metaplastic cancers of different tissue. We present the first known case report of male spindle cell carcinoma of the breast treated with KEYNOTE-522 regimen. Therapy included a first phase with pembrolizumab (dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin and second phase, with four cycles of pembrolizumab with doxorubicin-cyclophosphamide.

化生性乳腺癌(MBC)是一种罕见的肿瘤,通常表现为三阴性。MBC占所有乳腺癌的不到1%,梭形细胞变异占不到0.5%。梭形细胞癌虽然罕见,但却是西方世界最常见的亚型。与三阴性乳腺癌相比,它具有更具侵略性的生物学行为,其复发和死亡的风险增加。由于本病罕见,目前尚无治疗指南。相反,理论上的治疗是基于其他类型的侵袭性乳腺癌和不同组织的化脓性癌症的成功。我们提出了第一例已知的病例报告的男性梭形细胞癌的乳房治疗与KEYNOTE-522方案。治疗包括第一期每3周使用派姆单抗(剂量为200mg)加紫杉醇和卡铂,第二期使用4个周期的派姆单抗加阿霉素-环磷酰胺。
{"title":"KEYNOTE-522 and male spindle cell carcinoma of the breast: A case report.","authors":"Harper E Niver,&nbsp;Edward Foxhall,&nbsp;Anup Lahiry","doi":"10.1177/20363613231163730","DOIUrl":"https://doi.org/10.1177/20363613231163730","url":null,"abstract":"<p><p>Metaplastic Breast Cancer (MBC) is a rare group of tumors often presenting as triple-negative. MBC accounts for less than 1% of all breast cancers with the spindle cell variant comprising less than 0.5%. While rare, spindle cell carcinoma is the commonest subtype in the western world. It has a more aggressive biological behavior with increased risk of recurrence and death due to disease compared to triple negative breast cancers. There is no treatment guideline for management of MBC due to the rarity of the disease. Instead, treatment is theorized based off success with other types of aggressive breast and metaplastic cancers of different tissue. We present the first known case report of male spindle cell carcinoma of the breast treated with KEYNOTE-522 regimen. Therapy included a first phase with pembrolizumab (dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin and second phase, with four cycles of pembrolizumab with doxorubicin-cyclophosphamide.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"15 ","pages":"20363613231163730"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3a/cd/10.1177_20363613231163730.PMC10021088.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9152989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Treatment outcomes of adjuvant radiotherapy in adrenocortical carcinoma - A 13-years experience from a tertiary care centre. 辅助放射治疗肾上腺皮质癌的治疗结果-三级护理中心13年的经验。
IF 0.9 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.1177/20363613231160699
Divya Khosla, Rakesh Kapoor, Aditya K Singla, Kannan Periasamy, Shikha Goyal, Renu Madan, Narendra Kumar, Arunanshu Behera, Shrawan K Singh, Sanjay K Bhadada, Rama Walia

Purpose: Adrenocortical carcinoma (ACC) is a rare and highly aggressive malignant neoplasm, usually diagnosed in advanced stage. Role and efficacy of adjuvant radiotherapy has not been well defined. The objective of this study is to describe the various clinical characteristics and prognostic factors affecting the survival of ACC along with the role radiotherapy on overall survival and relapse free survival.

Methods: A retrospective analysis of 30 patients registered between 2007 and 2019 was carried out. The medical records containing clinical and treatment details were analysed. Data was analysed using SPSS 25.0. Survival curves were computed using Kaplan-Meier method. Univariate and multivariate analyses were performed to analyze the prognostic factors affecting the outcome. A p value of less than 0.05 was considered to be statistically significant.

Results: The median age of patients was 37.5 years (range, 5-72 years). 20 patients were females. Twenty-six patients had advanced stage (III/IV) disease while only four patients presented in early stage. Twenty-six patients underwent total adrenalectomy. Eighty three percent patients received adjuvant radiation therapy. The median follow up was 35.5 months (range, 7 monthss-132months). The estimated three- and 5-years overall survival (OS) was 67.2% and 23.3%, respectively. Capsular invasion and positive margins were the independent prognostic factors influencing both OS and relapse free survival (RFS). Out of 25 patients who received adjuvant radiation, only three patients had local relapse.

Conclusion: ACC is a rare and aggressive neoplasm with majority of patients presenting in advanced stage. Surgical resection with negative margins remains the mainstay of treatment. Capsular invasion and positive margins are independent prognostic factors for survival. Adjuvant radiation reduces the risk of local relapse and is well tolerated. Radiation can be used effectively in adjuvant and palliative settings in ACC.

目的:肾上腺皮质癌(ACC)是一种罕见的高侵袭性恶性肿瘤,通常在晚期诊断。辅助放疗的作用和疗效尚未明确。本研究的目的是描述影响ACC生存的各种临床特征和预后因素,以及放疗对总生存和无复发生存的作用。方法:对2007 - 2019年登记的30例患者进行回顾性分析。对包含临床和治疗细节的病历进行分析。数据采用SPSS 25.0进行分析。生存曲线采用Kaplan-Meier法计算。进行单因素和多因素分析,分析影响预后的因素。p值小于0.05认为有统计学意义。结果:患者中位年龄为37.5岁(范围5-72岁)。女性20例。26例为晚期(III/IV),仅有4例为早期。26例患者行全肾上腺切除术。83%的患者接受了辅助放射治疗。中位随访时间为35.5个月(范围7 -132个月)。估计3年和5年总生存率(OS)分别为67.2%和23.3%。囊膜浸润和阳性切缘是影响OS和无复发生存期(RFS)的独立预后因素。在接受辅助放疗的25例患者中,只有3例患者局部复发。结论:ACC是一种罕见的侵袭性肿瘤,以晚期肿瘤居多。手术切除阴性切缘仍然是主要的治疗方法。囊膜浸润和阳性切缘是独立的预后因素。辅助放疗降低了局部复发的风险,并且耐受性良好。在ACC的辅助治疗和姑息治疗中,放疗可以有效地应用。
{"title":"Treatment outcomes of adjuvant radiotherapy in adrenocortical carcinoma - A 13-years experience from a tertiary care centre.","authors":"Divya Khosla,&nbsp;Rakesh Kapoor,&nbsp;Aditya K Singla,&nbsp;Kannan Periasamy,&nbsp;Shikha Goyal,&nbsp;Renu Madan,&nbsp;Narendra Kumar,&nbsp;Arunanshu Behera,&nbsp;Shrawan K Singh,&nbsp;Sanjay K Bhadada,&nbsp;Rama Walia","doi":"10.1177/20363613231160699","DOIUrl":"https://doi.org/10.1177/20363613231160699","url":null,"abstract":"<p><strong>Purpose: </strong>Adrenocortical carcinoma (ACC) is a rare and highly aggressive malignant neoplasm, usually diagnosed in advanced stage. Role and efficacy of adjuvant radiotherapy has not been well defined. The objective of this study is to describe the various clinical characteristics and prognostic factors affecting the survival of ACC along with the role radiotherapy on overall survival and relapse free survival.</p><p><strong>Methods: </strong>A retrospective analysis of 30 patients registered between 2007 and 2019 was carried out. The medical records containing clinical and treatment details were analysed. Data was analysed using SPSS 25.0. Survival curves were computed using Kaplan-Meier method. Univariate and multivariate analyses were performed to analyze the prognostic factors affecting the outcome. A <i>p</i> value of less than 0.05 was considered to be statistically significant.</p><p><strong>Results: </strong>The median age of patients was 37.5 years (range, 5-72 years). 20 patients were females. Twenty-six patients had advanced stage (III/IV) disease while only four patients presented in early stage. Twenty-six patients underwent total adrenalectomy. Eighty three percent patients received adjuvant radiation therapy. The median follow up was 35.5 months (range, 7 monthss-132months). The estimated three- and 5-years overall survival (OS) was 67.2% and 23.3%, respectively. Capsular invasion and positive margins were the independent prognostic factors influencing both OS and relapse free survival (RFS). Out of 25 patients who received adjuvant radiation, only three patients had local relapse.</p><p><strong>Conclusion: </strong>ACC is a rare and aggressive neoplasm with majority of patients presenting in advanced stage. Surgical resection with negative margins remains the mainstay of treatment. Capsular invasion and positive margins are independent prognostic factors for survival. Adjuvant radiation reduces the risk of local relapse and is well tolerated. Radiation can be used effectively in adjuvant and palliative settings in ACC.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"15 ","pages":"20363613231160699"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/21/10.1177_20363613231160699.PMC9969472.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10824322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Epcoritamab-bysp (Epkinly) - A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma. Epkinly - Epcoritamab-bysp -弥漫性大b细胞淋巴瘤治疗的显著突破。
IF 0.9 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.1177/20363613231193566
Rumaisa Riaz, Afsheen Khan, Tasmiyah Siddiqui
The most prevalent non-Hodgkin lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), affects 25,000 people annually and accounts for roughly 30% of cases of Non-Hodgkin Lymphoma. 1 Rituximab and chemotherapy are commonly used in the treatment of diffuse large B-cell lymphoma (DLBCL) to cure the patient; however, a signi fi cant portion of patients, up to 40%, are bound to experience relapsed or refractory disease. In such cases, salvage chemotherapy followed by autologous stem cell transplantation is the standard approach, but less than half of the patients achieve long-term disease control. 2 Those who face refractory disease or experience relapse after transplantation have limited treatment options and generally have poor overall survival rates. 2,3 To address this unmet medical need, the Food and Drug Administration (FDA) has recently given Epcoritamab-bysp (Epkinly, Genmab US, Inc.) accelerated approval for the treatment of relapsed or refractory DLBCL, including cases where DLBCL arises from indolent lymphoma or high-grade B-cell lymphoma after two or more lines of systemic therapy. This approval signi fi es an important advancement, providing a potential therapeutic option for patients who have exhausted standard treatments. 4
{"title":"Epcoritamab-bysp (Epkinly) - A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma.","authors":"Rumaisa Riaz,&nbsp;Afsheen Khan,&nbsp;Tasmiyah Siddiqui","doi":"10.1177/20363613231193566","DOIUrl":"https://doi.org/10.1177/20363613231193566","url":null,"abstract":"The most prevalent non-Hodgkin lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), affects 25,000 people annually and accounts for roughly 30% of cases of Non-Hodgkin Lymphoma. 1 Rituximab and chemotherapy are commonly used in the treatment of diffuse large B-cell lymphoma (DLBCL) to cure the patient; however, a signi fi cant portion of patients, up to 40%, are bound to experience relapsed or refractory disease. In such cases, salvage chemotherapy followed by autologous stem cell transplantation is the standard approach, but less than half of the patients achieve long-term disease control. 2 Those who face refractory disease or experience relapse after transplantation have limited treatment options and generally have poor overall survival rates. 2,3 To address this unmet medical need, the Food and Drug Administration (FDA) has recently given Epcoritamab-bysp (Epkinly, Genmab US, Inc.) accelerated approval for the treatment of relapsed or refractory DLBCL, including cases where DLBCL arises from indolent lymphoma or high-grade B-cell lymphoma after two or more lines of systemic therapy. This approval signi fi es an important advancement, providing a potential therapeutic option for patients who have exhausted standard treatments. 4","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"15 ","pages":"20363613231193566"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/f3/10.1177_20363613231193566.PMC10392166.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10301535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary tracheal obstruction caused by adenoid cystic carcinoma during pregnancy: A case report. 妊娠期腺样囊性癌致原发性气管梗阻1例。
IF 0.9 Q4 Medicine Pub Date : 2022-11-01 eCollection Date: 2022-01-01 DOI: 10.1177/20363613221135015
Yongguo Xie, Ke Qin, Xueke Du, Shaopeng Ming, Lianmei Li, Chuangsheng Huang

The incidence of malignant tumors diagnosed during pregnancy is increasing, often ascribed to the recently recognized trend that many women are postponing childbirth. Although early diagnosis is optimal for both mothers and fetuses, the diagnosis of malignant tumors during pregnancy is often delayed until an advanced stage, because generalized symptoms of pregnancy and malignancy may overlap, such as shortness of breath, chest or abdominal discomfort. The study patient was 21 years old, and 31 weeks-pregnant when she was diagnosed with primary tracheal adenoid cystic carcinoma (ACC). The patient initially presented with dyspnea and decreased blood oxygen saturation and underwent a cesarean section on the first night of hospitalization, resulting from fetal distress. This case report intended to investigate potential barriers to the timely diagnosis of tracheal ACC and consider optimal management strategies when it is diagnosed during pregnancy.

怀孕期间诊断出的恶性肿瘤的发病率正在增加,这通常归因于最近认识到的许多妇女推迟分娩的趋势。虽然早期诊断对母亲和胎儿都是最佳的,但怀孕期间恶性肿瘤的诊断往往延迟到晚期,因为妊娠和恶性肿瘤的全身性症状可能重叠,如呼吸短促、胸部或腹部不适。该研究患者21岁,怀孕31周时被诊断为原发性气管腺样囊性癌(ACC)。患者最初表现为呼吸困难和血氧饱和度降低,住院第一晚因胎儿窘迫行剖宫产手术。本病例报告旨在探讨及时诊断气管ACC的潜在障碍,并考虑妊娠期诊断时的最佳管理策略。
{"title":"Primary tracheal obstruction caused by adenoid cystic carcinoma during pregnancy: A case report.","authors":"Yongguo Xie,&nbsp;Ke Qin,&nbsp;Xueke Du,&nbsp;Shaopeng Ming,&nbsp;Lianmei Li,&nbsp;Chuangsheng Huang","doi":"10.1177/20363613221135015","DOIUrl":"https://doi.org/10.1177/20363613221135015","url":null,"abstract":"<p><p>The incidence of malignant tumors diagnosed during pregnancy is increasing, often ascribed to the recently recognized trend that many women are postponing childbirth. Although early diagnosis is optimal for both mothers and fetuses, the diagnosis of malignant tumors during pregnancy is often delayed until an advanced stage, because generalized symptoms of pregnancy and malignancy may overlap, such as shortness of breath, chest or abdominal discomfort. The study patient was 21 years old, and 31 weeks-pregnant when she was diagnosed with primary tracheal adenoid cystic carcinoma (ACC). The patient initially presented with dyspnea and decreased blood oxygen saturation and underwent a cesarean section on the first night of hospitalization, resulting from fetal distress. This case report intended to investigate potential barriers to the timely diagnosis of tracheal ACC and consider optimal management strategies when it is diagnosed during pregnancy.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":"20363613221135015"},"PeriodicalIF":0.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/9b/10.1177_20363613221135015.PMC9629539.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40685690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reconstruction options in recurrent dermatofibrosarcoma protuberans:A scoping review. 复发性隆突性皮肤纤维肉瘤的重建选择:范围综述。
IF 0.9 Q4 ONCOLOGY Pub Date : 2022-11-01 eCollection Date: 2022-01-01 DOI: 10.1177/20363613221123951
Vishal Mago, Arush Pasricha

Background: This review will outline the evaluation, diagnosis, and management of dermatofibrosarcoma protuberans and emphasizes multidisciplinary role of nurses, plastic surgeons and radiation oncologist in this recurrent metastatic lesion. It pinpoints affected population at risk, clinical features, and reconstruction options. No analytical research has been done in this area.

Material and methods: A scoping review of patients of DFSP who underwent reconstruction after excision of tumors was performed in the Department of Burn and Plastic Surgery, AIIMS Rishikesh. It used a five framework approach. A review of 85 similar cases reported in the literature have been scrutinized in relation to the reconstruction options, sites of the tumor, margins of excision and recurrence.

Results: 85 full length English studies were included out of the 445 cases found in Pubmed and related search engines to reveal various reconstructive options in reconstruction of DFSP defects. Present scoping review identifies free anterolateral thigh flap to be useful in 7 review articles followed by propeller flaps in 3 isolated case reports. 2 cases of free latissimus dorsi flap were used for reconstruction of abdominal defects.

Conclusion: All patients should undergo a strict screening protocol where the health personnel can play a crucial role by educating parents on the follow up and report new lesions as early as possible. All operated tumor patients can be given safety tips and education on care and risks after reconstruction with skin flaps or skin grafting. A multidisciplinary approach between the surgeon, nurse and radiation oncologist is needed for effective management of these lesions.

背景:本文将概述隆突性皮肤纤维肉瘤的评估、诊断和治疗,并强调护士、整形外科医生和放射肿瘤学家在这种复发转移性病变中的多学科作用。它确定了受影响的高危人群、临床特征和重建选择。在这方面还没有做过分析研究。材料和方法:在AIIMS Rishikesh烧伤与整形外科对肿瘤切除后重建的DFSP患者进行了范围审查。它使用了五个框架方法。本文回顾了85例文献报道的类似病例,详细分析了重建选择、肿瘤位置、切除边缘和复发的关系。结果:在Pubmed及相关搜索引擎中检索到的445例病例中,共纳入85篇完整的英文研究,揭示了DFSP缺损重建的各种重建选择。目前的范围审查确定游离大腿前外侧皮瓣是有用的7篇综述文章,其次是螺旋桨皮瓣在3个孤立的病例报告。应用游离背阔肌皮瓣修复腹部缺损2例。结论:所有患者都应接受严格的筛查方案,其中卫生人员可以通过教育家长随访和尽早报告新病变发挥关键作用。所有手术后的肿瘤患者都可以接受安全提示,以及皮瓣或植皮重建后的护理和风险教育。外科医生,护士和放射肿瘤学家之间的多学科方法需要有效地管理这些病变。
{"title":"Reconstruction options in recurrent dermatofibrosarcoma protuberans:A scoping review.","authors":"Vishal Mago, Arush Pasricha","doi":"10.1177/20363613221123951","DOIUrl":"10.1177/20363613221123951","url":null,"abstract":"<p><strong>Background: </strong>This review will outline the evaluation, diagnosis, and management of dermatofibrosarcoma protuberans and emphasizes multidisciplinary role of nurses, plastic surgeons and radiation oncologist in this recurrent metastatic lesion. It pinpoints affected population at risk, clinical features, and reconstruction options. No analytical research has been done in this area.</p><p><strong>Material and methods: </strong>A scoping review of patients of DFSP who underwent reconstruction after excision of tumors was performed in the Department of Burn and Plastic Surgery, AIIMS Rishikesh. It used a five framework approach. A review of 85 similar cases reported in the literature have been scrutinized in relation to the reconstruction options, sites of the tumor, margins of excision and recurrence.</p><p><strong>Results: </strong>85 full length English studies were included out of the 445 cases found in Pubmed and related search engines to reveal various reconstructive options in reconstruction of DFSP defects. Present scoping review identifies free anterolateral thigh flap to be useful in 7 review articles followed by propeller flaps in 3 isolated case reports. 2 cases of free latissimus dorsi flap were used for reconstruction of abdominal defects.</p><p><strong>Conclusion: </strong><i>All patients should undergo a strict screening protocol where the health personnel can play a crucial role by educating parents on the follow up and report new lesions as early as possible. All operated tumor patients can be given safety tips and education on care and risks after reconstruction with skin flaps or skin grafting</i>. A multidisciplinary approach between the surgeon, nurse and radiation oncologist is needed for effective management of these lesions.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":" ","pages":"20363613221123951"},"PeriodicalIF":0.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dd/11/10.1177_20363613221123951.PMC9630893.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40685689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Rare Tumors
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1